Simulations Plus (SLP) Set to Announce Earnings on Wednesday

Simulations Plus (NASDAQ:SLP) is scheduled to release its earnings data after the market closes on Wednesday, October 23rd. Analysts expect Simulations Plus to post earnings of $0.04 per share for the quarter.

Simulations Plus Trading Down 0.7 %

Shares of NASDAQ:SLP opened at $31.50 on Wednesday. Simulations Plus has a 12-month low of $29.37 and a 12-month high of $51.22. The business’s fifty day simple moving average is $33.65 and its 200-day simple moving average is $41.18. The company has a market capitalization of $630.25 million, a PE ratio of 65.63 and a beta of 0.69.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total transaction of $792,600.00. Following the completion of the sale, the director now owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 60,750 shares of company stock worth $2,145,055 over the last 90 days. 20.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SLP has been the subject of several recent analyst reports. Craig Hallum reissued a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a report on Wednesday, July 3rd. KeyCorp started coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target for the company. JMP Securities started coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They set a “market perform” rating on the stock. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Thursday, September 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Simulations Plus has an average rating of “Moderate Buy” and an average target price of $56.00.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.